Define clinical exposure associated with QTc liability

Data Card

Early cardiac derisking: A clinically translatable hiPSC cardiomyocyte assay

Achieve action potential recordings from intrinsically paced hiPSC-CMs with Metrion’s clinically predictive hiPSC cardiomyocyte assay.

Simultaneous high-resolution measurement across 96 well plate at 10,000 Hz
Recordings using voltage-sensitive dye equivalent in quality to patch clamp
Multiple endpoints evaluated (APD20/50/90, rise time, beat rate, triangulation)
Measurement of acute (30min) and chronic (24h/48h) effects
Predicts clinical exposure associated with 10ms QTc prolongation
Defines exposure associated with QRS probability
Highlights unknown acute/chronic toxicity

Contact us for a quote or discussion

Recommended Publications

Latest Publications

Evaluation of hNav1.9 Screening Cascade for Analgesic Drug Discovery

Development of a robust hNaV1.9 high-throughput screening assay on the Sophion Qube384 platform. This is complemented by a suite of ion channel selectivity assays and sensory neuron recordings to create a versatile screening cascade to support NaV1.9 drug discovery programmes.

Simultaneous assessment of current response and ΔV½ enables sensitive characterisation of KV7 modulators across screening and profiling workflows

Reliable, high-throughput KV7 assays paired with expert interpretation enable faster progression of pain and epilepsy drug discovery programmes.

View All

Evaluation of hNav1.9 Screening Cascade for Analgesic Drug Discovery

Activation of TREK-1 and TREK-2 Two-Pore Domain Potassium Channels by the Kv4 Channel Modulator, NS5806

View All